The International Centre for Cancer Vaccine Science has proudly installed Poland’s first CGX10 Cell Isolation System – the most advanced and the only fully closed cell isolation technology designed for GMP-compliant cell production and sorting.

This new equipment will be a key tool in the isolation of cancer-specific T cells, enabling ICCVS researchers to accelerate the translation of innovative laboratory discoveries into clinical applications.

The CGX10 has been acquired as part of the project “Science for Welfare, Innovations and Forceful Therapies (SWIFT)”, implemented within the International Research Agendas Programme (IRAP) of the Foundation for Polish Science (FNP), with funding from the European Funds for a Smart Economy 2021–2027 (FENG).

With this milestone, ICCVS takes another significant step toward developing innovative, effective cancer therapies.